Literature DB >> 24415975

13th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).

Michael Untch1, Bernd Gerber2, Nadia Harbeck3, Christian Jackisch4, Norbert Marschner5, Volker Möbus6, Gunter von Minckwitz7, Sibylle Loibl8, Matthias W Beckmann9, Jens-Uwe Blohmer10, Serban-Dan Costa11, Thomas Decker12, Ingo Diel13, Thomas Dimpfl14, Wolfgang Eiermann15, Tanja Fehm16, Klaus Friese17, Fritz Jänicke18, Wolfgang Janni19, Walter Jonat20, Marion Kiechle21, Uwe Köhler22, Hans-Joachim Lück23, Nicolai Maass24, Kurt Possinger25, Achim Rody26, Anton Scharl27, Andreas Schneeweiss28, Christoph Thomssen29, Diethelm Wallwiener30, Anja Welt31.   

Abstract

The International Consensus Conference on the treatment of primary breast cancer takes place every two years in St. Gallen, Switzerland. The panel in St. Gallen is composed of international experts from different countries. From a German perspective, it seems reasonable to interpret the voting results in the light of AGO-recommendations and S3-guidelines for everyday practice in Germany. Consequently, a team of eight breast cancer experts, of whom two are members of the international St. Gallen panel, commented on the voting results of the St. Gallen Consensus Conference (2013). The main topics at this year's St. Gallen conference were surgical issues of the breast and axilla, radio-therapeutic and systemic treatment options, and the clinical relevance of tumour biology. The clinical utility of multigene assays for supporting individual treatment decisions was also intensively discussed.

Entities:  

Keywords:  Adjuvant therapy; Early breast cancer; Multigene signatures; St. Gallen Consensus; Targeted therapy

Year:  2013        PMID: 24415975      PMCID: PMC3728634          DOI: 10.1159/000351692

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  7 in total

1.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Authors:  Volker Moebus; Christian Jackisch; Hans-Joachim Lueck; Andreas du Bois; Christoph Thomssen; Christian Kurbacher; Walther Kuhn; Ulrike Nitz; Andreas Schneeweiss; Jens Huober; Nadia Harbeck; Gunter von Minckwitz; Ingo B Runnebaum; Axel Hinke; Rolf Kreienberg; Gottfried E Konecny; Michael Untch
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy.

Authors:  Alice Y Ho; Gaorav Gupta; Tari A King; Carmen A Perez; Sujata M Patil; Katherine H Rogers; Yong Hannah Wen; Edi Brogi; Monica Morrow; Clifford A Hudis; Tiffany Traina; Beryl McCormick; Simon N Powell; Mark E Robson
Journal:  Cancer       Date:  2012-03-05       Impact factor: 6.860

3.  Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

Authors:  Catherine M Kelly; Philip S Bernard; Savitri Krishnamurthy; Bailiang Wang; Mark T W Ebbert; Roy R L Bastien; Kenneth M Boucher; Elliana Young; Takayuki Iwamoto; Lajos Pusztai
Journal:  Oncologist       Date:  2012-03-14

4.  Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Authors:  Armando E Giuliano; Kelly K Hunt; Karla V Ballman; Peter D Beitsch; Pat W Whitworth; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Linda M McCall; Monica Morrow
Journal:  JAMA       Date:  2011-02-09       Impact factor: 56.272

5.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

6.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

7.  Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.

Authors:  Ewan K A Millar; Peter H Graham; Sandra A O'Toole; Catriona M McNeil; Lois Browne; Adrienne L Morey; Sarah Eggleton; Julia Beretov; Constantine Theocharous; Anne Capp; Elias Nasser; John H Kearsley; Geoff Delaney; George Papadatos; Christopher Fox; Robert L Sutherland
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

  7 in total
  48 in total

1.  Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Authors:  Shusma C Doebar; Leen Slaets; Fatima Cardoso; Sharon H Giordano; John Ms Bartlett; Konstantinos Tryfonidis; Nizet H Dijkstra; Caroline P Schröder; Christi J van Asperen; Barbro Linderholm; Kim Benstead; Winan Nm Dinjens; Ronald van Marion; Paul J van Diest; John Wm Martens; Carolien Hm van Deurzen
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

Review 2.  Tumor Bed Boost Integration during Whole Breast Radiotherapy: A Review of the Current Evidence.

Authors:  Pierfrancesco Franco; Domenico Cante; Piera Sciacero; Giuseppe Girelli; Maria Rosa La Porta; Umberto Ricardi
Journal:  Breast Care (Basel)       Date:  2015-02       Impact factor: 2.860

3.  Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.

Authors:  I Blancas; M Fontanillas; V Conde; J Lao; E Martínez; M J Sotelo; A Jaen; J L Bayo; F Carabantes; J J Illarramendi; M M Gordon; J Cruz; A García-Palomo; C Mendiola; E Pérez-Ruiz; J S Bofill; J M Baena-Cañada; N M Jáñez; G Esquerdo; M Ruiz-Borrego
Journal:  Clin Transl Oncol       Date:  2017-11-24       Impact factor: 3.405

4.  Radiation oncologists' view on the zurich consensus.

Authors:  Rainer Souchon; Marie-Luise Sautter-Bihl; Felix Sedlmayer; Frederik Wenz; Wilfried Budach; Rolf Sauer
Journal:  Breast Care (Basel)       Date:  2013-12       Impact factor: 2.860

5.  Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis.

Authors:  Chu Van Nguyen; Quang Tien Nguyen; Ha Thi Ngoc Vu; Khoa Hong Pham; Huyen Thi Phung
Journal:  Int J Clin Exp Pathol       Date:  2021-03-01

6.  Quality Assurance for Patients with Breast Cancer - the Impact of Clinical Cancer Registries.

Authors:  E C Inwald; M Klinkhammer-Schalke; M Koller; O Ortmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-09       Impact factor: 2.915

7.  Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer.

Authors:  Danmei Zhou; Kehan Ren; Jigang Wang; Hong Ren; Wenlin Yang; Wenjuan Wang; Qiong Li; Xiuping Liu; Feng Tang
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

8.  Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.

Authors:  Andrew J Epstein; Yu-Ning Wong; Nandita Mitra; Anil Vachani; Sakhena Hin; Lin Yang; Aaron Smith-McLallen; Katrina Armstrong; Peter W Groeneveld
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

9.  Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.

Authors:  Adrián Blanco-Gómez; Lourdes Hontecillas-Prieto; Roberto Corchado-Cobos; Natalia García-Sancha; Jesús Pérez-Losada; Sonia Castillo-Lluva; Nélida Salvador; Andrés Castellanos-Martín; María Del Mar Sáez-Freire; Marina Mendiburu-Eliçabe; Diego Alonso-López; Javier De Las Rivas; Mar Lorente; Ana García-Casas; Sofía Del Carmen; María Del Mar Abad-Hernández; Juan Jesús Cruz-Hernández; César Augusto Rodríguez-Sánchez; Juncal Claros-Ampuero; Begoña García-Cenador; Javier García-Criado; Akira Orimo; Thomas Gridley
Journal:  Cancer Res       Date:  2020-10-06       Impact factor: 12.701

10.  Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis--A short Report.

Authors:  Yanjie You; Haijun Li; Xin Qin; Yonggang Ran; Fei Wang
Journal:  Cell Oncol (Dordr)       Date:  2015-12-02       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.